CGEM
Cullinan Therapeutics, Inc.Company with tickers: CGEM
Market Cap
$1.13B
Shares Outstanding
61,458,046
CIK
1789972
CUSIP
230031106
13F Activity (30d)
1 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $53,697,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $42,123,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-53,697,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-45,485,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.75 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.75 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |